An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• The von Hippel-Lindau (VHL) gene is implicated in VHL disease and clear-cell renal cancer.
• VHL protein downregulates vascular endothelial growth factor (VEGF) transcription by inhibiting the Sp1 transcriptional activator.
• Previous studies established the VHL-Sp1 interaction's role in VHL's tumor suppressor function.

Purpose of the Study:

• To precisely map the VHL Sp1-binding domain.
• To investigate the functional significance of this domain in VHL's tumor suppressor activity.
• To explore additional VHL interactions and mechanisms of action.

Main Methods:

• Site-directed mutagenesis to identify the VHL Sp1-binding domain.
• Deletion analysis to assess the domain's contribution to VHL function.
• Analysis of VHL's effects on Sp1 DNA binding and target gene expression.

Main Results:

• The VHL Sp1-binding domain was mapped to amino acids 96-122.
• Mutations within the 96-122 domain disrupt the VHL-Sp1 interaction and impair VHL's tumor suppressor activity.
• Deletion of this domain prevents VHL from affecting Sp1 binding and target gene expression.
• Partial abrogation of VHL's repressor activity suggests additional effectors beyond Sp1.
• The 96-122 domain mediates VHL self-association and interaction with Sp1 zinc fingers, potentially binding other metalloproteins.

Conclusions:

• The VHL 96-122 amino acid domain is critical for VHL's interaction with Sp1 and its tumor suppressor function.
• This domain plays a key role in regulating VHL target gene expression.
• The findings suggest a more complex mechanism of VHL tumor suppression involving additional protein interactions and effectors.